WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will present clinical results from its QTORIN™ rapamycin program at the ISSVA World Congress 2026 in Philadelphia, with data from Phase 3 and Phase 2 studies accepted for a late-breaking session.
The presentation, scheduled for May 20, 2026, will include results from the Phase 3 SELVA study and Phase 2 TOIVA study evaluating QTORIN™ 3.9% rapamycin anhydrous gel in vascular malformations.
James Treat, a professor of clinical pediatrics and dermatology at Children’s Hospital of Philadelphia, will present the findings.
The studies evaluated the therapy in patients with microcystic lymphatic malformations and cutaneous venous malformations.
The company said the data demonstrated statistically significant and clinically meaningful improvements in these conditions.
The presentation will be available at the start of the session on the company’s website at https://palvellatx.com/publications-and-presentations/.
Palvella is developing QTORIN™ rapamycin as a treatment for rare skin diseases and vascular malformations and is also advancing additional candidates through its pipeline.
The therapy remains investigational and has not been approved by the U.S. Food and Drug Administration.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.